Janux Therapeutics, Inc. Incentive from Lessor
Janux Therapeutics, Inc. (JANX) had Incentive from Lessor of $700.00 thousand as of 2022-12-31, per its 10-K filed 2023-03-10.
Discontinued › Notes › Leases
us-gaap:IncentiveFromLessor · last filed 2023-03-10
- 2022-12-31: Incentive from Lessor $700.00K.
| Period end | Incentive from Lessor |
|---|---|
| 2022-12-31 | $700.00K 10-K · filed 2023-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |